14 Perspectives of Aptamers for Medical Applications
445
Table 14.4
(continued)
Molecular
target
Aptamer
Sponsor
Medical indications
Current status
Duration
FDA
approved
EYE001 (Anti-VEGF
Pegylated Aptamer)
Eyetech
Pharmaceuticals/National
Wet form of AMD;
Clinically Significant
Diabetic Macular
Edema (CSME)
Involving the Center of
the Macula
Phase 2/3, completed 2001-2007
No
Bevacizumab
Medical University of
Vienna
cancer
Phase3, completed
2008
yes
OPH2002
Ophthotech Corporation
Idiopathic Polypoidal
Choroidal
Vasculopathy
Phase2, completed
2015
No
VEGF165
Macugen (Pegaptanib
Sodium)
Retina Institute of Hawaii Retinal detachment
Phase3/4,complete
2005-2008
yes